SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
SystImmune是一家处于临床阶段的前沿生物制药公司，专注于开发用于癌症治疗的新型双特异性、多特异性抗体及抗体药物偶联物（ADCs）。公司今天宣布任命Jonathan Cheng博士为SystImmune新任首席医学官。在加入SystImmune之前，Cheng博士在百时美施贵宝担任高级副总裁兼肿瘤发展主管，负责管理抗肿瘤管线的临床后期开发。通过本次任命，Cheng 博士接替了Martin Olivo 博士，后者为寻求外部发展机会已离开SystImmune。
“I am excited to welcome Dr. Cheng to our leadership team,” said Jie D’Elia, Ph.D., Chief Ｅxecutive Officer of SystImmune. “His global oncology development expertise and in-depth regulatory knowledge will accelerate our efforts to advance SystImmune’s pipeline and transform patient care. On behalf of the SystImmune team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and contributions to SystImmune. We wish him well in his future endeavors.”
SystImmune首席执行官Jie D'Elia博士表示：“我很高兴并欢迎Cheng博士加入我们的领导团队。他在全球肿瘤药物开发领域的专业沉淀和对行业监管的深刻理解，将加速SystImmune的管线进度，并进一步推动我们对患者治疗的变革。我谨代表SystImmune团队，向Martin Olivo博士对公司的奉献表示深深的谢意。我们祝愿他在未来一切顺利。”
Dr. Yi Zhu, Chairman of SystImmune, stated “Dr. Cheng brings a wealth of expertise and a remarkable track record in oncology drug development, making him an invaluable addition to SystImmune’s Ｅxecutive leadership team.”
SystImmune董事长朱义博士表示：“Cheng博士在肿瘤药物开发领域拥有丰富的专业知识和卓越的业绩，他的加入让SystImmune领导团队更加壮大。”
Dr. Cheng’s career spans both the pharmaceutical industry and academia, where he has consistently demonstrated exceptional leadership and a passion for advancing cancer treatments. Under Dr. Cheng’s leadership, BMS developed and received regulatory approval for multiple important medicines, including Nivolumab, Ipilimumab, Relatlimab, and Repotrectinib. His strategic vision also enhanced BMS’s internal and collaboration portfolio. Previously, Dr. Cheng served as Therapeutic Area Head of Oncology at Merck and led teams in securing approvals for Pembrolizumab and Lenvatinib across multiple oncology indications. Prior to his career in the pharmaceutical industry, Dr. Cheng had a successful academic career at Fox Chase Cancer Center, where he conducted groundbreaking research as the principal investigator in tumor stromal biology, resulting in over 150 original manuscripts and abstracts. Dr. Cheng received a BS from Marquette University and an MD from the University of Minnesota.
Cheng博士的职业生涯跨越制药行业和学术界，在推动癌症治疗方面始终展现了非凡的领导能力和热情。在他的领导下，BMS开发并上市了多种重要药物，包括Nivolumab、Ipilimumab、Relatlimab和Repotrectinib。他的战略远见，增强了该公司内部产品线以及合作管线的竞争力。在加入BMS之前，Cheng博士为默沙东肿瘤临床研究副总裁，并领导团队取得Pembrolizumab和Lenvatinib在多个肿瘤适应症的上市获批。在进入制药行业之前，Cheng博士在 Fox Chase 癌症中心拥有成功的学术生涯。他作为肿瘤基质生物学的首席研究员，进行了开创性的研究，并形成150 多份原始手稿和摘要。Cheng博士获得马凯特大学学士学位和明尼苏达大学医学博士学位。
For further information, please contact: info@systimmune.com
如需更多信息，请联系:info@systimmune.com
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.
关于SystImmune
SystImmune是一家位于华盛顿州雷德蒙德的处于临床阶段的生物制药公司。该公司专注于利用其成熟的药物开发平台，开发创新的癌症治疗方法，包括双特异性、多特异性抗体及抗体药物偶联物（ADCs）。SystImmune在实体瘤和血液病领域的多个临床试验阶段均拥有管线和技术储备。除了正在进行的临床试验外，公司还拥有强大的临床前管线，包括处于发现阶段或IND阶段的潜在癌症治疗药物，代表着公司在生物制药开发领域的领先实力。
川公网安备 51011502000517号